title: Editorial Commentary: Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?
authors.affiliation: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Panozzo
authors.affiliation: Division of Epidemiology 1, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Christian
authors.initials: C
authors.lastname: Hampp
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000914:Antibodies, Viral / Q000008:administration & dosage*; D018890:Chemoprevention / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral
keywords: RSV; clinical guideline; palivizumab; respiratory syncytial virus; seasonality